ZD1839 (Gefitinib, ‘Iressa’), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma  by Teraishi, Fuminori et al.
FEBS 29738 FEBS Letters 579 (2005) 4069–4075ZD1839 (Geﬁtinib, Iressa), an epidermal growth factor
receptor-tyrosine kinase inhibitor, enhances the anti-cancer eﬀects
of TRAIL in human esophageal squamous cell carcinoma
Fuminori Teraishia, Shunsuke Kagawaa,b, Takanori Watanabea,
Yasuhisa Tangoc, Takeshi Kawashimaa, Tatsuo Umeokaa, Masahiko Nisizakia,
Noriaki Tanakaa, Toshiyoshi Fujiwaraa,b,*
a Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan
b Center for Gene and Cell Therapy, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
c Department of Surgery, Shiga University of Medical Science, Shiga 520-2192, Japan
Received 3 March 2005; revised 23 May 2005; accepted 9 June 2005
Available online 6 July 2005
Edited by Lukas HuberAbstract The EGF (epidermal growth factor) receptor-tyrosine
kinase inhibitor ZD1839 (Geﬁtinib, Iressa) blocks the cell sig-
naling pathways involved in cell proliferation, survival, and angi-
ogenesis in various cancer cells. TNF-related death apoptosis
inducing ligand (TRAIL) acts as an anticancer agent. We inves-
tigated the antitumor eﬀects of ZD1839 alone or in combination
with TRAIL against human esophageal squamous cell cancer
(ESCC) lines. Although all ESCC cells expressed EGF receptor
at a protein level, the eﬀect of ZD1839 on cell growth did not
correlate with the level of EGFR expression and phosphorylation
of EGF receptor protein in ESCC lines. ZD1839 caused a dose-
dependent growth arrest at G0–G1 phase associated with in-
creased p27 expression. As TE8 cells are resistant to TRAIL,
we tested whether ZD1839 combined with TRAIL induced apop-
tosis of TE8 cells via the inhibition of EGF receptor signaling by
ZD1839. ZD1839 inhibited the phosphorylation of Akt, and en-
hanced TRAIL-induced apoptosis via activation of caspase-3 and
caspase-9, and inactivation of Bcl-xL. Our results indicated that
ZD1839 has anti-cancer properties against human esophageal
cancer cells. ZD1839 also augmented the anti-cancer activity
of TRAIL, even in TRAIL-resistant tumors. These results sug-
gest that treatment with ZD1839 and TRAIL may have potential
in the treatment of ESCC patients.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Esophageal squamous cell cancer (ESCC) is associated with
a poor prognosis and high recurrence rate despite improve-Abbreviations: EGF, epidermal growth factor; EGFR, epidermal
growth factor receptor; ESCC, esophageal squamous cell carcinoma;
FACS, ﬂuorescence-activated cell-sorting; MTT, 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide; NSCLCs, non-small cell
lung cancers; PI, propidium iodide; PI3K, phosphatidylinositol 3-
kinase; TKI, tyrosine kinase inhibitor; TRAIL, tumor necrosis factor-
related apoptosis inducing ligand
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operation, chemotherapy and irradiation. Searching for molec-
ular targets of ESCC is critical to improve the eﬀect of treat-
ment [1–3]. According to recent reports, epidermal growth
factor receptor (EGFR) is highly expressed in invasive ESCC,
and patients with EGFR-overexpressing esophageal cancers
have a poorer prognosis and more lymph node metastases than
those with EGFR-negative tumors [4–6].
EGFR belongs to the type I receptor tyrosine kinase fam-
ily, which includes ErbB2/HER2, ErbB3, and ErbB4 and is
implicated in the cell proliferation, angiogenesis, invasion
and survival of neoplastic cells [7]. The regulation of these
family members is complex, as the receptors can be transac-
tivated by homodimeric interaction between two family
members and thus uses multiple pathways to execute their
biological functions [8]. The presence of deregulated
EGFR-tyrosine kinase (TK) has been conﬁrmed in many
types of solid tumors, such as head and neck cancers, colon
cancers, non-small cell lung cancers (NSCLC), and breast
cancers. Considered together, growth factors and their
receptors, therefore, play an essential role in cancer patho-
genesis and progression, and they are considered important
targets for anticancer therapy [9–11].
ZD1839 (Iressa, AstraZeneca) is an orally administered,
small-molecule EGFR-TK inhibitor (EGFR-TKI) that blocks
signal transduction pathways implicated in proliferation and
survival of cancer cells, as well as other host-dependent pro-
cesses that promote cancer growth. ZD1839 has broad antitu-
mor eﬀect against various types of solid tumors, including
NSCLC, colorectal, breast, and head and neck cancers [12–
14], and has been clinically approved for the treatment of
advanced NSCLC. Moreover, various additive/cooperative ef-
fects have been reported for many kinds of solid tumors both
in vitro and in vivo when ZD1839 is combined with other
chemotherapeutic agents or radiotherapy [15–17]. Based on
the above studies, ZD1839 is anticipated to exert antitumor
eﬀects on ESCC. When clinically assessed in a Phase II trial
as second-line treatment for advanced esophageal cancer, in
which 9 out of 36 enrolled patients had ESCC, a total of 3
patients (10%) had partial responses and seven patients
(23%) had stable disease [18]. The results were less than ideal
and multidisciplinary strategies are required.blished by Elsevier B.V. All rights reserved.
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(TRAIL) is a member of the TNF family and a potent proa-
poptotic ligand in broad variety of tumor cells but not in most
normal cells [19]. Interestingly, several recent reports have
shown that phosphorylated active Akt protected cancer cells
against TRAIL-induced apoptosis [20,21], and that EGFR-
TKI can inactivate Akt [22]. In this regard, a recent study also
reported that various ESCC cell lines were resistant to TRAIL
including TE8 cells [23]. These ﬁndings led us to hypothesize
that ZD1839 might potently enhance TRAIL-induced apopto-
sis of TRAIL-resistant cancer cells via inhibition of Akt phos-
phorylation secondary to EFGR TK inhibition. To test this
hypothesis, we designed the present study with the following
aims. First, to characterize the antitumor properties of
ZD1839 in ESCC cell lines. Second, to determine the intracel-
lular mechanisms of action of ZD1839 alone and/or when
combined with TRAIL by examining inhibition of EGFR
TK by ZD1839 on the phosphorylation of Akt and TRAIL-
mediated apoptosis of ESCC cells.
The results showed that inhibition of EGFR mediated Akt
phosphorylation by ZD1839 led to Bcl-xL inactivation and
caspase-9 activation in TE8 cells, thereby promoting apoptosis
of cells through a mitochondrial-dependent apoptotic path-
way. The ﬁndings suggest that treatment with ZD1839 alone
or in combination with TRAIL is a promising strategy for
ESCC.Fig. 1. Eﬀects of ZD1839 on cell growth in ESCC cells. (A) Detection
of EGFR, phosphorylation of EGFR, HER2, and phosphorylation of
tyrosine expression in human ESCC cells by Western blot analysis.
Sub-conﬂuent cells were treated with or without 10 ng/ml of EGF, and
then collected after 30 min. Equivalent amounts (50 lg) of protein
obtained from whole cell lysates were loaded in each lane, probed with
anti-EGFR, HER2 and phosphorylation of EGFR and tyrosine
antibody, and then visualized by using an ECL detection system. (B)
Eﬀect of ZD1839 on cell growth of human esophageal cancer cell lines.
Cells were plated in each well of triplicate 96-well plates and cultured
in the presence of indicated concentrations of ZD1839 for 72 h. Cell
viability was determined by the MTT assay. Growth of control cells
(not treated with ZD1839) was set at 100%. Each point represents the
mean ± S.D. of three independent experiments.2. Materials and methods
2.1. Cells and culture conditions
The human ESCC cell lines (TE1, TE6, TE8 and TTn) were propa-
gated in monolayer cultures in RPMI 1640 medium supplemented with
10% fetal calf serum (FCS), 25 mM 4-(2-hydroxyethyl)-1-piperazinee-
thanesulfonic acid (HEPES), 100 U/ml penicillin, and 100 mg/ml strep-
tomycin. ESCC cells were maintained under 5% CO2 at 37 C. Cells
were treated with the indicated concentration of ZD1839 (10–
100 lM) or TRAIL (0.1–500 ng/ml) for the indicated interval. TE8
cells were treated with 1 lM ZD1839 combined with or without
100 ng/ml TRAIL for various time intervals (1,3,6,12, and 24 h). Cells
were harvested, and prepared for each experiment as described below.
2.2. Reagents
ZD1839 (Geﬁtinib, Iressa) was a kind gift from AstraZeneca (Mac-
clesﬁeld, United Kingdom), dissolved in dimethyl sulfoxide (DMSO)
at 10 mM and stored at 20 C as a master stock solution. The drugs
were diluted in fresh media before each experiment. EGF was pur-
chased from Sigma Chemical Co. (St. Louis, MO), dissolved in DMSO
at 100 lg/ml, and stored at 20 C. Human recombinant TRAIL was
purchased from Calbiochem (San Diego, CA), dissolved in phosphate-
buﬀered saline (PBS) at 100 lg/ml, and stored at 80 C. In all exper-
iments, the ﬁnal DMSO concentration was <0.1%.
2.3. Cell proliferation assay
The cell growth inhibitory eﬀects of ZD1839 or/and TRAIL on
ESCC cells were determined using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay as described previously
[24]. Cell viability was calculated: 100 · Atreatment/Acontrol (%). The IC50
value was the concentration of ZD1839 that resulted in 50% inhibition
in absorbance according to the Curve Fit 1.3 program.
2.4. Flow cytometry analysis
Cells treated with various concentrations of ZD1839 were harvested
in 0.125% trypsin, washed twice in PBS with 2% FCS. After centrifu-
gation, 1 · 106 cells were resuspended in PBS containing 0.1% Triton
X-100 and 10 lg/ml RNase A (Sigma) for 5 min at room temperature.
The samples were then stained with 10 lg/ml propidium iodide (PI)[Sigma] and incubated at room temperature for 30 min. Cell cycle anal-
ysis was determined by the ﬂuorescence-activated cell sorter (FAC-
Scan) ﬂow cytometer with the Cell Quest software program (Becton
Dickinson Labware, Franklin Lakes, NJ). All experiments were re-
peated at least twice.
2.5. Antibodies and Western blot analysis
The following antibodies were used: anti-EGFR, cyclinD1 and Bcl-
xL (Santa Cruz Biotechnology, Santa Cruz, CA), anti-phospho-EGFR
(BioSource International Inc., Camarillo, CA), anti-HER2 (Neomar-
kers, Fremont, CA), anti-phospho-tyrosine (Upstate Biotechnology,
Lake Placid, NY), anti-phospho-Akt (Ser473, Upstate USA, Inc.,
Charlottesville, VA), Akt, Caspase-3, -7, -9, and PARP (Cell Signaling
Technology, Beverly, MA), anti-p21, p27, cdk4 (Transduction Labora-
tories, Lexington, KY), and anti-b-actin (Sigma). Cells were washed
twice in cold PBS and collected, then lysed in lysis buﬀer [10 mM Tris
(pH 7.5), 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 10% glycerol,
and 0.5% NP40] containing proteinase inhibitors (0.1 mM phenyl-
methylsulfonyl ﬂuoride, 0.5 mM Na3VO4). After 20 min on ice, the
lysates were spun at 14000 rpm in a microcentrifuge at 4 C for
10 min. The supernatants were used as whole cell extracts. Protein con-
centration was determined using the Bio-Rad protein determination
method (Bio-Rad, Richmond, CA). Equal amounts (50 lg) of proteins
were boiled for 5 min and electrophoresed under reducing conditions
on 6–12.5% (w/v) polyacrylamide gels. Proteins were electrophoreti-
cally transferred to a Hybond-polyvinylidene diﬂuoride (PVDF) trans-
fer membranes (Amersham Life Science, Buckinghamshire, UK), and
F. Teraishi et al. / FEBS Letters 579 (2005) 4069–4075 4071incubated with the primary, followed by peroxidase-linked secondary
antibody. An Amersham ECL chemiluminescent western system
(Amersham) was used to detect secondary probes.
2.6. Caspase-3 activity assay
TE8 cells in 10-cm dishes were treated with ZD1839 in the presence
or absence of TRAIL for 3 h and then harvested in cell lysis buﬀer. The
cell lysates were collected by centrifugation at 12000 rpm for 10 min,
and their protein concentration was evaluated using a Protein Assay
(Bio-Rad). Caspase-3 activity in cell lysates (25 lg) was determined
by using caspase-3 Fluorometric Protease Assay Kit (Medical & Bio-
logical Laboratories, Nagoya, Japan) according to the instructions
provided by the manufacturer. Fluorescence was detected using a ﬂuo-
rescence spectrometer at 400 nm excitation and 505 nm emission. The
relative caspase activity was determined as the level of substrate-
labeled AFC (7-amino-4-triﬂuoromethyl coumarin) cleavage in each
treated cell compared with that in control cells.
2.7. Statistical analysis
Data are expressed as mean ± S.D. Diﬀerences in the cell growth
inhibition eﬀect for the treatment groups were compared using the Stu-
dents t-test. Statistical signiﬁcance was deﬁned as P < 0.05.Fig. 2. ZD1839 induced cell cycle arrest at G1 phase in TE1 cells. (A) Weste
with 1 lM ZD1839 for 24 h after stimulation with EGF (10 ng/ml). (B) Phas
indicated concentrations or 0.01% DMSO were evaluated for 72 h after tre
ZD1839-treated cells. Magniﬁcation, 100·. (C) Eﬀects of ZD1839 on cell cyc
TE1 cells treated with vehicle or the indicated concentrations of ZD1839 fo
stained with 10 lg/ml PI at room temperature for 30 min. DNA content an
ﬂowcytometer, and the percentages of cells at G0/G1 phase were determined.
cells. Cells were treated with the indicated concentrations of ZD1839 for 24 h
Equivalent amounts (50 lg) of protein obtained from the whole cell extracts w
2 and then visualized by using an ECL detection system. b-actin was used t3. Results
3.1. Overexpression of EGFR and eﬀects of ZD1839 on cell
growth in human ESCC cells
ESCC cell lines expressed diﬀerent levels of EGFR, HER2,
phosphorylation of EGFR, and phosphorylation of tyrosine
determined by Western blot analysis (Fig. 1A). EGF, the spe-
ciﬁc ligand of EGFR, increased the level of phosphorylation of
EGFR and tyrosine, and was used as positive control in fur-
ther experiments. TE8 cells were autophosphorylated to
EGFR without EGF.
We next determined the eﬀects of ZD1839, an EGFR-TKI,
on the cell proliferation using the MTT assay. Cells were trea-
ted with various concentrations (0.01–100 lM) of ZD1839 for
3 days. ZD1839 induced diﬀerential cell growth inhibitory ef-
fects on four esophageal cancer cells (Fig. 1B). Treatment of
TE1 cells with 1 lM of ZD1839 decreased cell survival rate
by over 50%, suggesting that TE1 cells were the most sensitive
to ZD1839 among the cell lines used. However, treatment withrn blot analysis for phosphorylation of EGFR. TE1 cells were treated
e-contrast photomicrographs of TE1 cells treated with ZD1839 at the
atment. Note the signiﬁcant and dose-dependent growth inhibition in
le progression of TE1 cells. Flowcytometric analysis of asynchronous
r 72 h. After treatment, the cells were harvested and ﬁxed, and then
d change in cell cycle parameter (G0/G1) were analyzed by FACScan
(D) and (E) Western blot analysis of G0–G1 regulatory proteins in TE1
(D), or treated with 1 lM ZD1839 for the indicated time intervals (E).
ere loaded in each lane, probed with antibodies as described in Section
o ensure equal protein loading.
Fig. 3. ZD1839 inhibits EGF-induced phosphorylation of Akt in TE8
cells. (A) Expression of Akt and phosphorylation of Akt in human
esophageal cancer cells in the absence (mock) or presence of 10 ng/ml
EGF (EGF). Phosphorylation of Akt was highly expressed in TE8 cells
compared with another cell lines. (B) Eﬀects of ZD1839 on EGF-
stimulated EGFR phosphorylation and Akt activation in TE8 cells.
EGFR and Akt were phosphorylated within 10 min of EGF treatment.
The phosphorylation of EGFR and Akt was markedly inhibited by
pretreatment with ZD1839 (1 lM) for 30 min. , no pretreatment with
ZD1839; +, pretreatment with ZD1839.
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These results indicated that the eﬀect of ZD1839 did not cor-
relate with the level of EGFR expression. The mean IC50 val-
ues for ZD1839 were TE1 0.13, TE6 18.73, TE8 16.29, and
TTn 8.96 lM.
3.2. ZD1839 treatment induces G1 phase arrest and upregulation
of p27
To elucidate themechanisms of ZD1839 induced growth inhi-
bition in ZD1839-sensitive TE1 cells, we ﬁrst tested the eﬀects of
ZD1839 on the phosphorylation of EGFR. ZD1839 treatment
for 24 h downregulated phosphorylation of EGFR in TE1 cells,
while basal EGFR protein level did not change over the same
period (Fig. 2A). These data conﬁrmed that ZD1839 eﬀectively
inhibited TK-related phosphorylation of EGFR. Moreover,
treatment with ZD1839 resulted in inhibition of TE1 cell growth
but not control cells, as conﬁrmed by morphological examina-
tion (Fig. 2B). To determine the eﬀects of ZD1839 on the cell-
cycle proﬁle, TE1 cells were treated with 0–10 lM ZD1839 for
24 h and then the cell cycle distribution was analyzed by FACS.
The cell cycle was arrested at G1 phase in a ZD1839 dose-depen-
dent manner, but sub-G1 fraction indicative of apoptosis was
very small (Fig. 2C). Western blot analysis performed to evalu-
ate themolecules related to the cell cycle regulation revealed that
ZD1839 treatment of TE1 cells led to a slight increase in p21 pro-
tein level, and marked increase in p27 protein level in dose- and
time-dependent manners, but had no eﬀect on cyclin D1 and
cdk4 protein levels (Fig. 2D and E). These results suggest that
ZD1839 treatment induced cell cycle arrest at G1 phase via
induction of p21 and p27 rather than apoptosis.
3.3. ZD1839 inhibits phosphorylation of EGFR and PI3k-Akt
signaling pathway
ESCC cells expressed variable levels of the Akt and phos-
phorylated Akt, and EGF activated phosphorylation of Akt(Fig. 3A). In TE6 and TE8 cells, Akt was constitutively
phosphorylated and the level of phosphorylated Akt expres-
sion did not change with EGF treatment. TE1 cells showed
no phosphorylated Akt expression following EGF treatment,
whereas phosphorylation of Akt was induced with EGF in
TTn cells. We next examined whether ZD1839 treatment
inhibits phosphorylation of Akt as a downstream molecule
of EGFR in TE8 cells. TE8 cells were pretreated with
1 lM ZD1839 for 30 min, and then 10 ng/ml EGF was
added for the indicated time intervals. As we expected,
ZD1839 inhibited both the phosphorylation of EGFR and
Akt in TE8 cells within 1 h of ZD1839 treatment, while ba-
sal EGFR and Akt protein levels were not changed (Fig.
3B). These results indicated that ZD1839 does not only inhi-
bit phosphorylation of EGFR expression, but also blocked
the activation of phosphatidylinositol 3-kinase (PI3k)-Akt
pathway, including phosphorylation of Akt. As 1 lM of
ZD1839 was suﬃcient to inhibit phosphorylation of EGFR
as well as Akt, this concentration was used for further com-
bination experiments with TRAIL.3.4. ZD1839-augmented TRAIL-induced apoptosis of TE8 cells
involves activation of caspases and inactivation of Bcl-xL
Recently, one report demonstrated that various ESCC cell
lines including TE8 cells were resistant to TRAIL [23]. Other
studies showed that activation of the PI3k-Akt pathway ren-
dered several types of cancer cells resistant to TRAIL-induced
apoptosis [20,21]. In the next step, we investigated whether
ZD1839 could alter the TRAIL sensitivity of TE8 cells via
Akt inactivation. In fact, TE8 cells overexpressing phosphory-
lated EGFR and Akt, and treatment with 500 ng/ml TRAIL
did not signiﬁcantly inhibit cell growth, suggesting that TE8
cells are resistant to TRAIL. Moreover, TTn cells were also
insensitive to 500 ng/ml TRAIL, and more resistant to TRAIL
treatement than TE8 cells (Fig. 4A). We further examined the
eﬀects of TRAIL on the growth of TE8 and TTn cells in vitro
in the presence or absence of ZD1839. As shown in Fig. 4B, a
synergistic increase in the growth inhibition rate was observed
in TE8 cells treated with 100 ng/ml of TRAIL combined with
1 lM of ZD1839 for 24 h. TRAIL alone inhibited cell growth
in approximately 17.5% of the cells, while treatment with
ZD1839 and TRAIL further inhibited cell growth in 46.1%
of the cells. ZD1839 alone had little eﬀect on tumor cell viabil-
ity (11%). We also found that treatment of TTn cells with
2 lM ZD1839 and 500 ng/ml TRAIL resulted in a marked
inhibition of cell growth compared with TRAIL alone or
ZD1839 alone; the magnitude of the synergism in TTn cells,
however, was less dramatic than that in TE8 cells, presumably
due to the increased resistance in TTn cells. Microscopic exam-
ination showed numerous dead TE8 cells treated for 24 h with
TRAIL plus ZD1839, indicating apoptosis of these cells (Fig.
4C). Interestingly, ZD1839 or TRAIL alone had little eﬀect
on caspase-3 activity, but the combination with ZD1839 and
TRAIL resulted in a marked increase of caspase-3 activity
3 h after treatment (Fig. 4D). In addition, the result of Western
blotting showed no eﬀect for ZD1839 or little eﬀect for TRAIL
on the processing of caspase-3 or PARP. In contrast, the com-
bination of ZD1839 and TRAIL resulted in cleavage of both
of caspase-3 and PARP (Fig. 5A). Taken together, these re-
sults indicate that ZD1839 augmentes TRAIL-induced apop-
tosis of TRAIL-resistant TE8 cells.
Fig. 4. Treatment with ZD1839 and TRAIL enhanced TE8 and TTn cell death. (A) Eﬀect of TRAIL on TE8 and TTn cell growth. Cells were plated
in each well of triplicate 96-well plates and cultured in the presence of various concentrations of TRAIL for 24 h. Cell viability was determined by the
MTT assay. Viability of cells of the control group was set at 100%. Data are mean ± S.D. values of triplicate determinations. (B) TE8 and TTn cells
were plated in triplicate at a density of 3 · 103 cells/well in the 12-well culture plates, and treated with either 1 or 2 lM of ZD1839 with or without
TRAIL (100 ng/ml for TE8 and 500 ng/ml for TTn) for 24 h, respectively. Cell viability was determined by MTT assay. Each point represents the
mean ± S.D. of three independent experiments. TRAIL alone versus ZD1839 plus TRAIL, P < 0.01; ZD1839 alone versus ZD1839 plus TRAIL,
P < 0.005. (C) Phase-contrast photomicrographs of TE8 cells treated with ZD1839 plus TRAIL was described for 24 h after treatment. Cells treated
with 0.01% DMSO alone were also used as control. Note the cell death (ﬂoating cells) of ZD1839 plus TRAIL-treated cells. Magniﬁcation, 100·. (D)
Caspase-3 activity in TE8 cells, treated with ZD1839 (1 lM) in the presence or absence TRAIL (100 ng/ml) for 3 h. Data are mean ± S.D. values of
triplicate determinations.
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changes of Bcl-xL, Bcl-xS and caspase-9 protein by Western
blotting. ZD1839 induced a slight induction of Bcl-xS protein.
Moreover, ZD1839 plus TRAIL downregulate Bcl-xL, and
activated caspase-9 (Fig. 5B). These ﬁndings suggest that the
augmentation of TRAIL-induced apoptosis by ZD1839 is
mediated by an increase in active caspase-9, which is consid-
ered to be mediated by downregulation of Bcl-xL.4. Discussion
ESCC is an aggressive human malignancy and prognosis is
poor except for a few patients with early stage ESCC.
Although the currently used chemotherapeutic agents have im-
proved the outcome of patients with advanced ESCC, their
eﬃcacies are still limited and they may cause serious toxicity.
Therefore, there is a general agreement for the identiﬁcation
of new therapeutic targets and development of new agents withhigh eﬃcacy and tolerability [25,26]. Recently, a wide variety
of molecular targets involved in the initial development and
progression of ESCC have been identiﬁed. Certainly, EGFR
could potentially be one such factor as it is overexpressed in
most ESCCs [4]. These ﬁndings led us to test the antitumor ef-
fect of ZD1839 against ESCC cells.
The results of cell proliferation assay showed that ZD1839
inhibited the cell growth of four ESCC cell lines in a dose-
dependent manner. The cell growth inhibitory eﬀect of
ZD1839 varied, with TE1 cells being the most sensitive, TTn
cells being moderate, and TE6 and TE8 cells being the least
sensitive. Although TE8 cells overexpressed both non-phos-
phorylated and phosphorylated EGFR, which were much
more than TE1 cells, the antitumor activity of ZD1839 on
TE8 cells was less than that on TE1 cells. This means that
the antitumor activity of ZD1839 against ESCC cells is not re-
lated to EGFR expression or phosphorylation of EGFR pro-
teins. These results are consistent with those of previous
study, which showed that the growth inhibition of several
Fig. 5. ZD1839 combined with TRAIL activated caspase-3, caspase-9
and PARP in TE8 cells. (A) TE8 cells were treated with ZD1839
(1 lM) and/or TRAIL for the indicated time intervals. (B) Regulation
of caspase-9 and Bcl-xL protein in TE8 cells treated with ZD1839 and/
or TRAIL. TE8 cells treated with ZD1839 (1 lM) in the presence or
absence TRAIL (100 ng/ml) for 3 h. Cell lysates were probed for both
cleaved caspase-9 and Bcl-xL by in Western blot analysis.
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late with the expression level of EGFR [27].
ZD1839 inhibited phosphorylation of EGFR at concentra-
tions between 1.0 and 10 lM in TE1 cells. In addition, the re-
sults of ﬂow cytometric analysis showed that ZD1839 resulted
in a dose-dependent increase of cell cycle arrest at G1 phase in
TE1 cells, whereas these eﬀects were not observed in other cell
types (data not shown). This diversity in cell cycle arrest may
account for the diﬀerences observed in growth inhibition be-
tween TE1 cells and other cells in MTT assay. Several reports
have previously shown that EGFR inhibition and resultant in-
crease in p27 expression correlated with accumulation of cells
with cell cycle arrest at G1 phase. When p27 expression was
blocked by an antisense oligonucleotide, only a small propor-
tion of cells in G1 phase was observed [28,29]. Similar ﬁndings
were been observed in human malignant pleural mesothelioma
cell lines treated with ZD1839 [30]. Our results are consistent
with these ﬁndings. We also demonstrated that ZD1839 in-
duced a slight increase in p21 protein expression in TE1 cells.
p21 is known as an inducer of cell cycle arrest at G1 phase [24].
In this regard, it has been reported that AG1478, an ErbB ki-
nase inhibitor, reduced cyclin D1 and cdk4 before it increased
p27 expression in BT-474 breast cancer cells [31]. Cyclin D1
and cdk4 are well known as the main regulators of cell cycle
progression through the G1-S transition. However, our results
showed that ZD1839 treatment had no eﬀect on cyclin D1 and
cdk4 in TE1 cells. The underlying mechanisms of the diﬀer-
ences in TE1 and other ESCC cells remain to be clariﬁed in fu-
ture studies.
Akt/PI3K, the downstream signaling of ErbB, is a key mol-
ecule in the control of neoplastic cell proliferation, apoptosis,
and angiogenesis [32–34]. Inhibition of PI3K signaling path-
way by various chemicals delays tumor development and en-
hances the activity of death-inducing ligands, such as TRAIL
[35,36]. In addition, previous reports showed that the PI3Ksignaling pathway plays an essential role in regulating cells
to escape from TRAIL-induced apoptosis [20,21,37–40]. Our
results of MTT assays showed that ZD1839 combined with
TRAIL signiﬁcantly inhibited the cell growth after 3 h treat-
ment. Furthermore, the results of caspase-3 assay suggest that
ZD1839 is a potent enhancer of TRAIL-induced apoptosis.
Our results also showed that the combination treatment de-
creased Bcl-xL. In this context, it has been reported that over-
expression of Bcl-xL in ESCC blocked TRAIL-induced
apoptosis at mitochondria level [23]. Other investigators
showed that EGFR inhibitors enhanced TRAIL-induced
apoptosis following decrease of phosphorylated active Akt
and Bcl-xL [41]. Based on these ﬁndings, we propose that stim-
ulation of TRAIL-induced apoptosis by ZD1839 is mediated
by caspase-9 activation via Bcl-xL down regulation following
Akt dephosphorylation. Our future plan encompasses further
examination of the mechanisms of ZD1839 and TRAIL action
in TE8 cells. In summary, our results emphasized the anti-cancer
properties of ZD1839 in esophageal cancer cells. Furthermore,
we showed that ZD1839 augmented TRAIL-induced apopto-
sis of TRAIL-resistant ESCC cells by activating mitochondrial
apoptotic pathway through inhibition of Akt phosphorylation.
Based on these properties, both agents are potentially suitable
adjuvant for the treatment of esophageal squamous cell
carcinoma. Further studies on theirs eﬃcacy and safety in
vivo are required in order to demonstrate potential clinical
application.
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